Last updated on April 2017

BAY1436032 in Patients With Mutant IDH1(mIDH1) Advanced Acute Myeloid Leukemia (AML)


Brief description of study

To determine the maximum tolerated and / or recommended Phase II dose of oral mutant IDH1 (mIDH1) inhibitor BAY1436032 and to characterize its safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical efficacy in patients with mIDH1-R132X advanced acute myeloid leukemia (AML)

Clinical Study Identifier: NCT03127735

Contact Investigators or Research Sites near you

Start Over

Bayer Clinical Trials Contact

University of Southern California Keck School of Medicine
Los Angeles, CA United States
  Connect »

Bayer Clinical Trials Contact

University of Florida-Gainesville
Gainesville, FL United States
  Connect »

Bayer Clinical Trials Contact

Northside Hospital - Atlanta
Atlanta, GA United States
  Connect »

Bayer Clinical Trials Contact

Northwestern Memorial Hospital
Chicago, IL United States
  Connect »

Bayer Clinical Trials Contact

University of Chicago
Chicago, IL United States
  Connect »

Bayer Clinical Trials Contact

Roswell Park Cancer Institute
Buffalo, NY United States
  Connect »

Bayer Clinical Trials Contact

Mount Sinai Medical Center
New York, NY United States
  Connect »

Bayer Clinical Trials Contact

Montefiore Medical Center
The Bronx, NY United States
  Connect »

Bayer Clinical Trials Contact

Wake Forest Baptist Health
Winston-Salem, NC United States
  Connect »

Bayer Clinical Trials Contact

Ohio State University
Columbus, OH United States
  Connect »

Bayer Clinical Trials Contact

University of Pennsylvania
Philadelphia, PA United States
  Connect »

Bayer Clinical Trials Contact

Thomas Jefferson University
Philadelphia, PA United States
  Connect »

Bayer Clinical Trials Contact

University of Texas MD Anderson Cancer Center
Houston, TX United States
  Connect »

Bayer Clinical Trials Contact

Universit tsklinikum Heidelberg
Heidelberg, Germany
  Connect »

Bayer Clinical Trials Contact

Klinikum rechts der Isar
München, Germany
  Connect »

Bayer Clinical Trials Contact

Medizinische Hochschule Hannover (MHH)
Hannover, Germany
  Connect »

Bayer Clinical Trials Contact

Universit tsklinikum Essen
Essen, Germany
  Connect »

Bayer Clinical Trials Contact

Universit tsklinikum Leipzig A R
Leipzig, Germany
  Connect »

Bayer Clinical Trials Contact

Universit tsklinikum Charite zu Berlin
Berlin, Germany
  Connect »

Bayer Clinical Trials Contact

Universit tsklinikum Hamburg Eppendorf (UKE)
Hamburg, Germany
  Connect »